Innovation & Enterprise


UCL-developed technology for prostate cancer acquired by US firm

24 January 2020

UCL spinout company SmartTarget has licensed its technology, which helps guide prostate cancer procedures, to US-based Intuitive Fusion.

SmartTarget logo

SmartTarget provides accurate, easy-to-use and affordable medical image fusion solutions for guiding prostate cancer biopsy and minimally-invasive cancer treatments. Its unique technology is based on research by scientists and engineers within UCL’s Centre for Medical Image Computing (CMIC). 

SmartTarget has now concluded a deal for the sale of its technology and assets to Intuitive Fusion LLC, owner of the Focalyx Suite, a state of the art platform for the delivery of biopsy and focal therapy procedures. 

As part of the deal, UCL Business Ltd (UCLB), the commercialisation company of UCL and a shareholder of SmartTarget Ltd, has entered into a licence agreement granting exclusivity of the underlying patents and core software to Intuitive Fusion. You can find out more on UCLB’s website.